Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study

The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%. The purpose of this study is to prospectively investigate the incidence of oxaliplatin allergy and neurotoxicity, and to evaluate the use of effective anti-allergic and desensitization therapies to enable patients who are already allergic to oxaliplatin to complete their prescribed doses smoothly.

开始日期2023-09-01

申办/合作机构

福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心）

NCT05298683

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

This is an investigator-initiated (IIS), phase 2, prospective, open-label, multinational study, designed to be conducted in approximately 14 sites. Eligible patients will initially receive six 28-day cycles of isatuximab, pomalidomide, and low-dose dexamethasone.
Following this phase:
Patients who achieve ≥VGPR will be randomized in a 1:1 ratio to receive isatuximab, given either Q2W or once monthly, plus pomalidomide and low-dose dexamethasone.
Patients with The study will last for 42 months (recruitment and follow-up period), starting from the date of the first patient in (FPI) to the date of the last patient last visit (LPLV).
Core study procedures consist of baseline and post-baseline safety and disease evaluations, including physical examination, hematologic/clinical chemistry tests, radiologic assessments, bone marrow evaluations, and blood/urine M-protein assessments.
Patients will be allowed to continue treatment until disease progression, death, unacceptable AEs, lost to follow-up, or consent withdrawal.

开始日期2022-05-01

申办/合作机构

Hellenic Society of Cardiology

[+1]

NCT04891250

/ Withdrawn临床4期IIT

The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19

The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU and transition probabilities to ICU (ventilator).

开始日期2021-10-01

申办/合作机构

Centre For Infectious Disease Research

[+1]

100 项与盐酸雷尼替丁相关的临床结果

登录后查看更多信息

100 项与盐酸雷尼替丁相关的转化医学

登录后查看更多信息

100 项与盐酸雷尼替丁相关的专利（医药）

登录后查看更多信息

6,128

项与盐酸雷尼替丁相关的文献（医药）

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

A hybrid LMO MOF catalytic membrane with PMS activation for efficient degradation of pharmaceutical micropollutants and nanoplastics removal

作者: Sharmin, Afia ; Bhuiyan, Muhammed A. ; Pramanik, Biplob Kumar

In this study, a novel hybrid CoFe layered metal oxide (CoFeLMO) membrane was developed by integrating metal-organic framework (MOF) MIL(100)Fe and polyethylene glycol (PEG), designed specifically for peroxymonosulfate (PMS)-based advanced oxidation processes.The uniqueness of this research lies in the innovative incorporation of LMO, MOF, and PEG nanosheets onto a polyethersulfone (PES) substrate, creating a highly efficient catalytic membrane for the simultaneous removal of pharmaceutical micropollutants and nanoplastics (NPs).Among various configurations, the LMO-MOF-PEG membrane, with 20% MOF (0.025 M) and 0.5 g of PEG, demonstrated superior performance, achieving remarkable removal efficiencies of 99.5% for ranitidine and 98.5% for NPs.This membrane also exhibited outstanding operational efficiency, achieving a flux of 1600 L/m2/h/bar at a low PMS concentration of 0.2 mM.The degradation of ranitidine was driven by both reactive species (SO^•-₄, ^•OH and O^•-₂) and non-reactive species (singlet ¹O₂), with SO^•-₄ playing a dominant role.Post-activation anal. revealed the presence of Co²⁺ and Fe²⁺ in both + II and + III oxidation, indicating the active participation of metal plots in the degradation process and confirming the membrane's reusability.The membrane demonstrated exceptional durability, maintaining a flux recovery ratio of 97-99% across 10 filtration cycles, even under harsh chem. conditions and across a wide pH range (2-12).Furthermore, Co leaching was minimal (2-21μg/L) over a broad pH spectrum, even after 15 days of immersion in water.

2025-06-01·SEPARATION AND PURIFICATION TECHNOLOGY

Schottky junctions integrated with S-scheme heterojunctions in recyclable loaded ZnIn2S4/UiO-66/calcined graphite felt photocatalysts with enhanced carrier separation for photocatalytic degradation

作者: Li, Yanan ; Miao, Rui ; An, Jiajun ; He, Miaolu ; Wang, Lei ; Gao, Bo ; Wang, Jinqiao ; Wang, Xudong

Photocatalytic technol. holds significant potential in the purification of antibiotic wastewater.However, efficient carrier separation and convenient recyclability are crucial for the practical application of photocatalysts.Herein, a loaded ZnIn₂S₄/UiO-66/calcined graphite felt (ZU/C-GF) composite photocatalyst was demonstrated to achieve efficient and stable removal of tetracycline hydrochloride (TCH) from water.Detailed characterization and theor. calculations suggested that ZnIn2S4 could form a Schottky junction with C-GF and an S-scheme heterojunction with UiO-66.The internal elec. field (IEF) at the interface could promote the migration of photoelectrons, while the Schottky barrier could inhibit electron backflow.This synergistic strategy maximized the separation of photogenerated electrons and holes, thereby enhancing the photocatalytic performance.The optimal composite material exhibited the highest removal efficiency (97.0 %) and reaction rate (0.02312 min^-1 ) while maintaining comparable degradation performance under solar irradiationAddnl., this C-GF-based immobilization scheme allowed for rapid recovery and reuse of the photocatalyst, effectively addressing the challenge of recycling.ZU-10/C-CF demonstrated stable reusability after five consecutive cycles, revealing its significant potential for practical applications.This work presents novel insights for coupling Schottky junctions and S-scheme heterojunctions, and describes a more convenient approach for the continuous and stable treatment of antibiotic wastewater.

2025-05-01·APPLIED CATALYSIS B-ENVIRONMENTAL

Ti3C2-based MXene anchoring single-atom Co as a long-lasting peroxymonosulfate activator enabling efficient water decontamination: Deciphering the critical role of titanium vacancies

作者: Xie, Haijiao ; Li, Huanxin ; Ma, Yiyang ; Wang, Hongjie ; Xue, Hao ; Xin, Yue ; Li, Qiang ; Dong, Yanzhi ; Zhang, Yue

Cobalt atoms anchored on Ti₃C₂-based MXene (i.e., Co-SA/MXene) have been successfully endowed with exceptional catalytic performance for the elimination of aqueous micropollutants.Herein, we firstly proposed a coupling method of etching-exfoliation-reduction to enrich titanium vacancies.The as-synthesized Co-SA/MXene exhibited a superior removal efficiency of ranitidine of 100 %, and the corresponding reaction kinetics constant (μmol/s•g) was 1.11-6643.53 times higher than the state-of-the-art for ranitidine degradationThe introduction of abundant titanium vacancies enabled a long-lasting life via an accelerated valence cycling of Co(II) and Co(III), and also effectively inhibited toxic Co² ⁺ leaching.DFT revealed that O_II/O_III dual-atoms were more suitable for PMS adsorbing while offering stronger adsorption energy, and further offered a new insight into the PMS activation mechanism for ¹O₂ selected generation.This work revealed that oxidation behavior of ranitidine and established an attractive water treatment technique for the rapid removal of aqueous micropollutants.

226

项与盐酸雷尼替丁相关的新闻（医药）

2025-03-09

·药事纵横

不可忽视的创新药理化性质之溶解度

只有溶解状态的药物才能发挥生物学作用，溶解度是影响药物生物利用度的重要因素之一。对创新药而言，无论是发现阶段还是开发阶段，对溶解度的研究都是至关重要的工作。一、溶解度定义溶解度是指在一定条件下，化合物在溶剂介质中达饱和时所能达到的最高浓度，溶解度不是化合物固有属性，取决于诸多因素，如化合物结构（可电离基团、亲脂性基团、氢键）、溶液中引入化合物的物理状态（固态、液态）、溶剂的组成和物理状态（溶剂种类、助溶剂及含量、溶液成分、酸碱度、温度）、测定方法（平衡时间、分离技术、检测手段）等。二、创新药对溶解度的阶段性考量创新药研发可笼统分为发现阶段和开发阶段（临床前研究、临床研究）。在发现阶段我们致力于将化合物溶解成溶液来进行生物测定和初步概念验证，因此多采用万能溶剂DMSO提高化合物溶解度，这一阶段的工作与动力学溶解度高度相关。而在开发阶段，主要目的是筛选合适的剂型以及完成注册申报所要求完成的详细技术研究，此时继续使用DMSO作为溶剂既有可能误导产生错误的结论。加上此时药物晶型已基本确定，采用热力学溶解度来表征溶解度对制剂开发具有很好的指导作用。热力学溶解度：也称平衡溶解度，是向晶态化合物中直接加入水系溶剂，经过长时间混合后使已溶解物质和固态物质达到平衡状态。热力学溶解度常用于指导制剂开发和制定开发策略、诊断体内结果同时也是申报资料的重要文件组成。动力学溶解度：将化合物溶解于有机良溶剂中（通常为DMSO），然后被缓缓加入水系溶剂介质中。动力学溶解度常被用于开发用于动物给药的通用制剂、建立化合物结构-溶解度关系、警示存在的吸收或生物测定易变性、诊断错误的生物测定结果。过饱和稳定性提到动力学溶解度和热力学溶解度，这里还有一个跟两者都相关的概念，即过饱和稳定性。假设我们获得了一个活性或安全性都非常具有吸引力的化合物，但溶解度很低，且低溶解度与其他构效关系相关联（不易通过结构优化解决溶解度问题），此时是否只有放弃继续开发一条路可以走呢？答案是否定的。此时，可以将低热力学溶解度化合物分为具有低过饱和稳定性和高过饱和稳定性两类，对于高过饱和稳定性化合物（尤其是体内实现过饱和）具有较好的发展前景。人体的胃肠道是易发生过饱和现象的场所，例如碱性化合物在胃液中溶解良好，当来到小肠时因pH改变溶解度降低，有析出的风险，但化合物如具有较高够饱和倾向可减少或避免析出，提高生物利用度。在体外研究中，通常采用FaSSIF介质模拟胃肠道来进行体内过饱和稳定性的测定，如果一种化合物在FaSSIF中没有表现出可接受的热力学溶解度或过饱和稳定性，它可能代表最坏的情况，并标志较高的开发风险。三、溶解度接受标准在创新药研发中我们常常会面临这样的问题，化合物所需的最低溶解度是多少？这个问题没有绝对的答案。发现阶段溶解度的评价目的是指导化合物选择与推进。此阶段对于最低溶解度需求，William Curatolo等人提出了最大剂量理论，即MAD与溶解性和渗透性之间的关系。MAD=S*Ka*SIWV.SITT，其中S为溶解度（mg/mL，pH6.5），Ka为渗透率（min-1），SIWV为小肠水容量（约为250 mL），SITT为小肠经过时间（约为270min）。化合物剂量越低，渗透性越好，达人体最大吸收时所需的溶解度越低，反之亦然。例如有三个候选化合物A、B、C，其拟定计量、渗透率均已知，计算出各自所需的最低溶解度，结果见下表。表1在给定剂量和渗透率下，达目标吸收所需的最低可接受溶解度可以看出化合物A和B具有相同的最大吸收剂量，化合物A的渗透率是B的十倍，计算所得化合物A的最低可接受溶解度是B的十分之一；化合物A与化合物C具有相同渗透率，但化合物C的最大吸收剂量是A的十倍，计算所得化合物C的最低可接受溶解度是A的十倍；化合物C最大吸收剂量是B的十倍，化合物C的渗透率也是B的十倍，经计算化合物C的最低可接受溶解度与B相同。同样基于MAD理论，Lipinski依据经验对剂量和渗透率的低、中、高水平赋予确定的数值，剂量低中高水平分别为0.1 mg/mL、1 mg/mL和10 mg/mL，渗透率的低中高水平分别为0.005 min-1、0.02 min-1和0.1min-1，并依据此经验数据将溶解度与剂量和渗透性之间的关系用图形更直观的表示出来。图1最低可接受溶解度示意图（图片来源于文献4）由上图可知，如果化合物渗透性足够好，最大吸收剂量最够低（效价足够高），那么即便化合物溶解度仅有1 μg/mL也是可以不借助药剂学手段或结构修饰就能进一步开发的。开发阶段进入开发阶段常被用于回答最低可接受溶解度问题就是大名鼎鼎的BCS生物学分类系统，该系统按照溶解性和渗透性将化合物分为4类。 I类：高溶高渗，是理想的口服吸收药物，多为两亲性化合物，如阿巴卡韦、对乙酰氨基酚、阿米洛利、阿托品、美托洛尔、依那普利、地尔硫卓、去甲替林等，体内吸收的限制因素为溶出度。 II类：低溶高渗，多为亲脂性化合物，如胺碘酮、阿托伐他汀、阿奇霉素、环丙沙星、苯妥英、萘普生、双氯芬酸、地高辛、双氯芬酸、吡罗昔康等，体内吸收量的限制因素是溶解度，可通过制剂学手段来提高该类化合物的溶解度。 III类，高溶低渗，多为亲水性化合物，如阿昔洛韦、西咪替丁、阿莫西林、阿替洛尔、二膦酸盐、红霉素、雷尼替丁、头孢唑啉等，吸收速率的限制因素是渗透性，可通过前药技术提高渗透性。 IV类，低溶低渗，通常无法预期体内体外相关性，开发此类化合物风险较大，如两性霉素、紫杉酚、特非那定、新霉素、甲氨蝶呤、环丙沙星、呋塞米、氢氯噻嗪等。基于文献数据的BCS分类体统溶解性可用D0（既定计量下250 mL中药物浓度与药物在水中饱和溶解度之比）评价，D0≤1为高溶解性，D0＞1为低溶解性；渗透性可粗略用亲脂性指标logP来评价，以美托洛尔（logP1.72）为标杆，logP大于美托洛尔的定义为高渗透性，logP低于美托洛尔的定义为低渗透性。当然，如果药物肠道吸收是载体介导的，光凭亲脂性评价渗透性会有较大偏差。四、溶解度的影响因素影响溶解度的因素的包括结构特征和生理环境。结构特征包括亲脂性、分子大小、解离常数和晶格能等，生理环境包括胃肠道生理环境、种属差异和食物的影响。五、提升溶解度的手段当候选化合物溶解度不理想时，研发团队必将致力于提升溶解度，优化手段包括结构修饰、制剂策略等，但首选结构修饰，将问题解决节点前置，避免将过多难题留给制剂团队。常见的结构修饰手段见下图。六、结论新药开发面临着多重挑战。有人形容新药发现过程就像玩杂耍，为达到成功需要同时监控不同参数的组合并维持平衡。溶解度就是其中一个重要参数。然而溶解度并不是孤立的数值，会受到物理环境和生理环境等多种因素影响。对溶解度研究的同时也应关注溶解度与其他因素的相互影响，进行多参数优化。虽然不能保证候选化合物一定在临床中成功，但它可以增加开发过程成功的机率。参考文献 [1]Cunliang Zhang，Equilibrium solubility, Hansen solubility parameter, dissolution thermodynamics, transfer property and preferential solvation of zonisamide in aqueous binary mixtures of ethanol, acetonitrile, isopropanol and N,N-dimethylformamide，Journal of Molecular Liquids 326 (2021) 115219. [2] Suzanne M. Skolnik, Automated supersaturation stability assay to differentiate poorly soluble compounds in drug discovery, Journal of Pharmaceutical Sciences, Volume 107, Issue 1, January 2018, Pages 84-93 [3] Srini Venkatesh, Role of the Development Scientist in Compound Lead Selection and Optimization, JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 89, NO. 2, FEBRUARY 2000,145-154. [4] Christopher A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability, Journal of Pharmacological and Toxicological Methods 44 (2000) 235- 249. [5]William Curatolo,Physical chemical properties of oral drug candidates in the discovery and exploratory developmentsettings,research focus,PSTT Voll 1(9) ,1998,387-393. [6]Kevin C .Johnson,Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption,Pharmaceutical Research,13(12),1996,1795-1798. [7] Arik Dahan, Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs, The AAPS Journal, Vol. 11, No. 4, December 2009,740-746. [8]类药性质：概念、结构设计与方法：从ADME到安全性优化 [9]Ramu Samineni,Emerging Role of Biopharmaceutical Classification and Biopharmaceutical Drug Disposition System in Dosage form Development: A Systematic Review,Turk J Pharm Sci 2022;19(6):706-713 药事纵横投稿须知：稿费已上调，欢迎投稿

诊断试剂

2025-03-05

·EndPoints

Trump administration reverses lease termination for major FDA quality lab in St. Louis

Two days after announcing plans to shut down an FDA lab devoted to ensuring the US drug supply remains safe and potent, the Trump administration has changed plans and will leave the lab open, Endpoints News has learned. The St. Louis lab, known as the Office of Testing and Research, is one of the drug agency’s most important facilities for ensuring drugs are of high quality. In addition to its day-to-day work, the lab has been called in to investigate high-profile drug safety issues. In 2008, for example, it led a probe into contaminated supplies of the blood thinner heparin, which likely killed dozens of Americans and was eventually traced back to a supplier in China. More recently, it led a probe into common heartburn medications that were found to have unsafe levels of nitrosamine, a carcinogen. That investigation helped lead to popular products like Zantac and related over-the-counter drugs being pulled from shelves. “They are the FDA’s premier drug analysis lab,” former FDA Acting Commissioner Janet Woodcock told Endpoints by email. “Congress has been constantly on FDA to make sure imported drugs are of adequate quality, and the St. Louis lab is the foundation of that.” The lab was one of about 30 FDA facilities whose leases were marked for termination by Elon Musk’s Department of Government Efficiency, or DOGE, which has been charged with slashing government spending but has sometimes had to reverse course on its actions when it has taken steps to shut down critical government functions. As of Wednesday afternoon, the lease for the lab was still posted on DOGE’s “Wall of Receipts.” DOGE claimed on the site that ending the lease on the 50,000 square-foot St. Louis lab, which recently underwent a $10 million renovation, would save $20 million. In some other cases, DOGE’s inaccurate claims of cost savings have been pulled from its website. DOGE has also said it has reversed other sudden cuts — such as to an Ebola prevention program (reporting by the Washington Post has shown that the Ebola program hadn’t been restored , as of last week). FDA and HHS spokespeople didn’t immediately respond to requests for comment. A spokesperson from the federal government’s General Services Administration did not respond to Endpoints’ inquiry on the St. Louis lab and instead said it’s working to secure suitable alternative space for any canceled leases. Additional details of the planned closure, and then the action to reverse it two days later, were relayed to Endpoints by two scientists at the facility who had been briefed by FDA leadership. Endpoints is not naming them to protect them from retaliation. “We’re relieved our lab won’t close,” one of the researchers said. But they added that they expect more cuts to come to the agency: “We know we are not in the clear … regarding our jobs or our work.” On Monday, staff at the lab were told that the lease for the facility was being terminated. It wasn’t clear where staff would go, or if their jobs would remain. Equally important, it wasn’t clear what would happen to hundreds of millions of dollars in characterization and testing equipment that’s used to evaluate drugs, or where those activities would be redirected. “The decision to terminate the St. Louis lab will cost more money than it saves,” one scientist at the lab told Endpoints on Tuesday. The two scientists, and other people familiar with the lab’s work, described the research and testing conducted there as essential for ensuring the availability of complex generics and biosimilars in the US. The ISO-certified testing and research lab in St. Louis serves the FDA’s wide-ranging Office of Pharmaceutical Quality.

2025-02-25

·EndPoints

Boehringer Ingelheim wins jury verdict in Zantac retrial in Illinois

An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the company confirmed. The verdict followed two mistrials in the plaintiffs’ cases last year that ended in hung juries. Ronald Kimbrow and Martin Gross argued in separate lawsuits that they developed prostate cancer after taking the popular heartburn medication. Thousands of similar lawsuits alleging Zantac caused several types of cancer have been filed against Boehringer Ingelheim, GSK, Sanofi and Pfizer, all of which owned the rights to Zantac at some point. The jury sided with Boehringer after less than two hours of deliberation in an Illinois state court, according to the company. “While Boehringer sympathizes with both plaintiffs, the outcome of this case is entirely consistent with the totality of the scientific evidence, which shows that Zantac does not cause any type of cancer,” a Boehringer spokesperson told Endpoints News on Monday. “We are pleased with the jury’s verdict and will vigorously defend all remaining cases.” Zantac was approved as a prescription medicine for heartburn in 1983, leading to record sales and eventually several over-the-counter versions. But the drug is no longer sold in the US. The FDA asked manufacturers to pull it from the market immediately in 2020, after finding that levels of a probable carcinogen called NDMA could increase in Zantac over time, especially when stored at high temperatures.

上市批准专利侵权

100 项与盐酸雷尼替丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00673	盐酸雷尼替丁	A02BA02	DB00863

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
反流性食管炎	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-08-13
胃泌素瘤	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-08-13
局部硬皮病	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-08-13
胃溃疡	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-08-13
胃酸过多	中国	湖南正清制药集团股份有限公司	1985-01-01
十二指肠溃疡	美国	GSK Plc	1983-06-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管反流	临床2期	澳大利亚	GSK Plc	2006-05-01
胃灼热	临床2期	澳大利亚	GSK Plc	2006-05-01
HIV感染	临床2期	美国	Glaxo Wellcome SA	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01847001 (CTgov)	临床2期	局部晚期恶性肿瘤 \| 乳腺癌	10	Surgery+Trastuzumab+nab-paclitaxel+CYCLOPHOSPHAMIDE+DOT imaging+doxorubicin+Paclitaxel+Decadron+pertuzumab+ranitidine+Benadryl+Propranolol	窪顧壓衊醖艱鹽艱夢繭(網廠蓋願簾繭蓋憲鹽餘) = 鏇膚積醖築夢鑰範蓋顧鬱蓋襯鏇積糧蓋範鹹網 (鹹齋鑰獵鏇鹹網廠獵鏇, 願窪獵淵艱糧網餘齋齋 ~ 觸繭鹹範窪鹽積鏇築蓋) 更多	-	2020-01-10
EULAR2016	N/A	-	24	Ranitidine	鬱夢廠網簾糧衊餘廠鹽(遞衊鹹憲顧構鏇鹽鑰壓) = 構遞鏇淵構艱觸齋製積願築積選觸選範繭膚鏇 (糧顧鬱夢鹹憲製鹽繭艱 ) 更多	-	2016-06-08
EULAR2016	N/A	-	24	Control (saline solution)	鬱夢廠網簾糧衊餘廠鹽(遞衊鹹憲顧構鏇鹽鑰壓) = 蓋鏇遞選淵齋鬱遞構齋願築積選觸選範繭膚鏇 (糧顧鬱夢鹹憲製鹽繭艱 ) 更多	-	2016-06-08
AAAAI2016	N/A	药物不良反应	-	Ranitidine	鹹獵選遞壓餘淵簾齋壓(築鹽鹽獵夢廠襯餘鏇廠) = Among them, 99 patients (17.0%) experienced anaphylaxis 鏇鏇醖餘憲鬱觸艱遞衊 (艱鑰淵壓觸鬱淵衊構齋 )	-	2016-02-01
NCT00668317 (CTgov)	临床3期	呼吸道过敏 \| 咳嗽	5	Omeprazole+Ranitidine	選鹽範獵憲製壓築網艱(積築壓繭廠衊窪獵築膚) = 淵獵積積範齋淵範簾憲遞醖觸淵製簾築憲鹹廠 (繭窪淵遞壓觸鑰鹹鹹範, 0.479)	-	2012-11-16
NCT00030992 (CTgov)	临床2期	肾细胞癌	102	BMS-247550+Ranitidine+Diphenhydramine	餘艱壓獵憲齋蓋願憲襯 = 衊網觸鹹鹽選壓範繭艱選獵繭糧膚遞壓憲鏇繭 (鹹構範壓廠範鏇築範構, 遞獵糧鑰鬱夢糧蓋壓鬱 ~ 願糧艱鑰製艱顧遞觸顧) 更多	-	2012-07-20
Pubmed \| N Engl J Med	N/A	十二指肠溃疡 Helicobacter pylori	104	Amoxicillin plus Metronidazole	顧鑰餘齋鹹網積衊製鏇(鑰蓋鬱積獵窪簾糧鬱遞) = mainly diarrhea 選壓壓獵膚壓顧餘遞鹹 (遞鹹淵鬱糧繭醖願齋衊 ) 更多	积极	1993-02-04
Pubmed \| N Engl J Med	N/A	十二指肠溃疡 Helicobacter pylori	104	Placebo		积极	1993-02-04